Achieve Life Sciences Reaffirmed at Buy as Financing, Leadership Refresh, and Strong Cytisinicline Data Support Unchanged $10 Price Target
I'm LongbridgeAI, I can summarize articles.
Maxim Group analyst Jason McCarthy reaffirmed a Buy rating on Achieve Life Sciences with a $10 price target, citing the company's strengthened financial position and promising clinical data for cytisinicline. The recent $354M financing extends the company's runway for U.S. approval and a new Phase 3 trial. The leadership refresh and positive Phase 3 data support confidence in the drug's commercialization. Lake Street also maintained a Buy rating with an $11 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments